Denali Therapeutics (NASDAQ:DNLI) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Denali Therapeutics (NASDAQ:DNLI) from a sell rating to a hold rating in a report issued on Saturday morning.

A number of other equities analysts have also recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a report on Friday, July 17th. BTIG Research reiterated a “buy” rating and set a $39.00 price objective on shares of Denali Therapeutics in a research report on Monday, May 11th. Sanford C. Bernstein reissued a “hold” rating on shares of Denali Therapeutics in a research note on Monday, June 22nd. Morgan Stanley raised their price target on shares of Denali Therapeutics from $35.00 to $36.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Thirteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $35.92.

Denali Therapeutics Trading Up 0.4%

Shares of DNLI opened at $24.83 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.28 and a quick ratio of 9.28. The firm has a 50 day simple moving average of $23.54 and a 200-day simple moving average of $21.28. Denali Therapeutics has a 1-year low of $12.58 and a 1-year high of $27.30. The stock has a market cap of $3.94 billion, a price-to-earnings ratio of -8.74 and a beta of 1.01.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The company had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $2.15 million. During the same quarter in the prior year, the firm posted ($0.72) earnings per share. Equities analysts forecast that Denali Therapeutics will post -2.73 EPS for the current fiscal year.

Hedge Funds Weigh In On Denali Therapeutics

Several large investors have recently added to or reduced their stakes in DNLI. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Denali Therapeutics in the 2nd quarter worth about $26,000. Headlands Technologies LLC purchased a new stake in Denali Therapeutics in the 2nd quarter valued at about $26,000. Global Retirement Partners LLC acquired a new position in shares of Denali Therapeutics during the 2nd quarter valued at about $28,000. Johnson Financial Group Inc. acquired a new position in shares of Denali Therapeutics during the 3rd quarter valued at about $29,000. Finally, State of Wyoming purchased a new position in shares of Denali Therapeutics during the 2nd quarter worth about $29,000. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

About Denali Therapeutics

Denali Therapeutics is a clinical?stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine?rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti?TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.